Sun Pharma

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Stocks to Watch, Nov 29: Here are few stocks that will remain in focus for today's session

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company wins its appeal, or up to two years if it loses the case entirely

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the line, ICICI Securities expects some negative impact on the company

Shares of Sun Pharmaceuticals, the biggest pharmaceutical company of India fell 1.71 per cent at Rs 1870 per share on the BSE after brokerages offered mixed reviews post Q2

The company launched 14 new products in India this quarter

Sun Pharmaceutical Industries on Monday reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in the September quarter. The drug major had posted a net profit of Rs 2,375 crore in the July-September quarter of last fiscal. Total income rose to Rs 13,645 crore in the second quarter compared to Rs 12,486 crore in the year-ago period, the Mumbai-based drug major said in a regulatory filing. "Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercialising late stage candidate Fibromun, upon approval," Dilip Shanghvi, Chairman and Managing Director of the company, said. With Fibromun, the company's product basket for dermatologists has expanded further, he added. "We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market," Shanghvi said. Shares of the company were trading 2.22 per cent higher at Rs 1,901.55 apiece on the BSE.

Q2FY25 company results: Indian Oil, Ambuja Cements, Aditya Birla Sun Life AMC, Sun Pharma and more will report their second-quarter earnings on October 28

Analysts expect Sun Pharma to register double digit growth in the topline and bottomline driven by specialty sales

ONGC, Oil India, GNFC, Tata Chemicals and Sun Pharma are among the 9 stocks that could rally up to 20%, suggests technical charts. Check key support and resistance levels for these stocks here.

Sun Pharmaceutical Industries on Tuesday said it has inked a global licensing pact with Italian-Swiss firm Philogen for an anti-cancer drug. As per the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun, a speciality product of Philogen. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. As per the pact, Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorisation with regulatory authorities, and manufacture commercial supplies, the Mumbai-based drug major said in a statement. Sun Pharma will be responsible for commercialisation activities, it added. The two partner companies will share post-commercialisation economics in about 45(Philogen):55(Sun Pharma) ratio, Sun Pharma said. The company did not disclose other financial terms. "Fibromun's progress through development has been qui

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

Starizo is used to treat Acute Bacterial Skin and Skin Structure Infection.

Markets experienced a breather after the recent decline, gaining over a percent, driven by strong global cues.

On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.7 crore reported in Q3 FY24, respectively

Big Pharma companies Cipla, Sun Pharma, Aurobindo Pharma, Dr Reddy's, and Lupin face intense scrutiny from the US Food and Drug Administration (USFDA)

Autoimmune disorder characterised by hair loss affects some 700,000 people in the US

Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit

This came after Sun Pharmaceuticals announced that the US Food and Drug Administration (USFDA) has approved its new drug application for Deuruxolitinib, a new treatment for Alopecia Areata